#1 Clinical Trials Search in Europe

Almagate

This article discusses a Phase IV clinical trial investigating the safety of Almagate, an antacid medication, in pregnant women experiencing heartburn and reflux. The study aims to assess the effects of Almagate on both the mother and the developing fetus, as well as perinatal outcomes in newborns. This multicenter, open-label, single-arm study will provide valuable insights into the use of Almagate during pregnancy and its potential impact on maternal and fetal health.

Table of Contents

What is ALMAGATE?

ALMAGATE is a medication primarily used to treat heartburn and reflux, particularly in pregnant women[1]. It belongs to a class of drugs known as antacids, which help neutralize stomach acid. The brand name for ALMAGATE is Almax Forte, and it comes in the form of an oral suspension (a liquid medication that you drink)[1].

Medical Conditions Treated

ALMAGATE is specifically designed to treat:

  • Heartburn: A burning sensation in the chest often caused by stomach acid flowing back into the esophagus.
  • Reflux: Also known as acid reflux or gastroesophageal reflux disease (GERD), where stomach contents flow back into the esophagus, causing discomfort and potential damage[1].

Safety in Pregnancy

One of the key features of ALMAGATE is its potential safety for use during pregnancy. A clinical study is currently being conducted to evaluate the safety of ALMAGATE in pregnant women with heartburn and reflux, as well as its effects on the developing fetus and newborn[1]. This study focuses on women in their second and third trimesters of pregnancy.

How ALMAGATE Works

ALMAGATE works by neutralizing excess stomach acid. This helps to relieve the symptoms of heartburn and reflux, providing comfort to those experiencing these conditions[1].

Dosage and Administration

ALMAGATE is taken orally as a suspension. The maximum daily dose is 8 grams, and the maximum total dose over a treatment period is 112 grams. The typical treatment period lasts up to 14 days[1]. However, always follow your doctor’s instructions regarding dosage and duration of treatment.

Effectiveness

The ongoing clinical study aims to evaluate the efficacy of ALMAGATE in reducing heartburn and reflux in pregnant women. Patients and physicians will assess the effectiveness of the medication after each episode of heartburn or reflux, rating it from “very poor” to “very good”[1].

Potential Side Effects

While the current study is specifically looking at the safety profile of ALMAGATE, it’s important to note that all medications can have potential side effects. The study is monitoring various outcomes, including:

  • Gestational diabetes
  • Hypertensive states of pregnancy
  • Complications during delivery
  • Effects on the newborn, including birth weight and development[1]

Who Should Not Use ALMAGATE

Based on the exclusion criteria of the ongoing study, ALMAGATE may not be suitable for pregnant women who:

  • Are in their first trimester of pregnancy
  • Have a high-risk pregnancy
  • Have been diagnosed with Alzheimer’s disease
  • Have high blood pressure
  • Have diabetes mellitus
  • Have undiagnosed gastrointestinal or rectal bleeding
  • Are hypersensitive to ALMAGATE or any of its ingredients[1]

Ongoing Research

A Phase IV clinical trial is currently underway to further evaluate the safety and efficacy of ALMAGATE in pregnant women. This study will follow participants through their pregnancy and monitor the development of their children up to 24 months of age. The research aims to provide more comprehensive data on the use of ALMAGATE during pregnancy and its potential effects on both mother and child[1].

Aspect Details
Study Type Phase IV, multicenter, open-label, single-arm
Participants Pregnant women aged 18-45 with heartburn
Main Objective Assess safety of Almagate in pregnant women and perinatal outcomes
Secondary Objectives Evaluate efficacy of Almagate, assess patient satisfaction, monitor newborn development
Duration Estimated 36 months (including 24-month follow-up of newborns)
Key Outcomes Gestational diabetes, hypertensive states, perinatal mortality, maternal mortality, low birth weight
Exclusion Criteria First trimester pregnancy, high-risk pregnancy, previous antacid use during current pregnancy

FAQ

  • What is the main purpose of this clinical trial? The main purpose of this clinical trial is to assess the safety of Almagate in pregnant women with heartburn and reflux, and to evaluate perinatal outcomes in the fetus and newborn.
  • Who can participate in this study? Adult pregnant women aged 18-45 years with heartburn can participate. However, women in their first trimester of pregnancy, those with high-risk pregnancies, or those who have used other antacids during this pregnancy are not eligible.
  • How long will the study last? The maximum study duration is estimated to be 36 months, which includes follow-up of the newborn's development up to 24 months of age.
  • What outcomes will be measured in this trial? The trial will measure various outcomes, including gestational diabetes, hypertensive states of pregnancy, perinatal mortality, maternal mortality, low birth weight, and the newborn's development up to 24 months of age.
  • How will the effectiveness of Almagate be evaluated? The effectiveness of Almagate will be assessed at each follow-up visit by both the physician and the patient, rating the experience as 'very good,' 'good,' 'acceptable,' 'poor,' or 'very poor' in treating heartburn and reflux.

Ongoing Clinical Trials on Almagate

  • Safety Study of Almagate for Pregnant Women with Heartburn and Reflux, Assessing Effects on Mother and Baby

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Almagate: An antacid medication used to treat heartburn and reflux symptoms.
  • Phase IV clinical trial: A type of clinical study conducted after a drug has been approved for use, to gather additional information about its safety, effectiveness, and optimal use.
  • Perinatal outcomes: Health outcomes related to the time immediately before and after birth, typically from 28 weeks of pregnancy to 28 days after birth.
  • Heartburn: A burning sensation in the chest, often caused by stomach acid flowing back into the esophagus.
  • Reflux: A condition where stomach contents flow back into the esophagus, causing discomfort and potential complications.
  • Gestational diabetes: A type of diabetes that develops during pregnancy in women who didn't have diabetes before becoming pregnant.
  • Pre-eclampsia: A pregnancy complication characterized by high blood pressure and signs of damage to other organ systems, most often the liver and kidneys.
  • Abruptio placentae: A serious pregnancy complication where the placenta partially or completely separates from the inner wall of the uterus before delivery.
  • Perinatal mortality: The number of stillbirths and deaths in the first week of life per 1,000 total births.
  • Low birth weight: A birth weight of less than 2,500 grams (5 pounds, 8 ounces), regardless of gestational age.
  • ASQ-3™ questionnaire: A developmental screening tool used to assess a child's progress in five areas: communication, gross motor, fine motor, problem-solving, and personal-social skills.

References

  1. http://clinicaltrials.eu/trial/safety-study-of-almagate-for-pregnant-women-with-heartburn-and-reflux-assessing-effects-on-mother-and-baby/